Alerte De Sécurité sur Trade name: Nuclisens Lysis Buffer (Lise Nuclisens Buffer). Technical name: Buffers, Electrolytic Solutions, Diluents and other Solutions for Laboratory Analysis. ANVISA registration number: 10158120527. Risk class: I. Model affected: N / A. Serial numbers affected: Lot: 17022802

Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.

Required actions: We request the following actions at the moment: - Send the "Product Safety Correction Notice" to the NucliSENS® Lysis Buffer product (Reference: 200292) to users who received impacted lot 17022802, in order to receive the information associated with this Field Action - Destroy any remaining stock of NucliSENS® Lysis Buffer (Reference: 200292) lot 17022802 which may still exist in the company stock. you may have with respect to the previously reported results, with your Laboratory Medical Officer, to determine the appropriate course of action.Contact bioMérieux customer service if you notice the problem.If you wish to notify technical grievances and events Adverse events (AE) and technical complaints (QT) for products subject to Health Surveillance should be done through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link Additional information: - Date of identification of the problem by the company: 07/13/2017 - Date of notification notice to Anvisa: 09/28/2017 The company that owns the affected product is responsible for contacting its customers in a timely manner. to ensure the effectiveness of the Field Action in progress. It stands out the joint responsibility of the distribution chain and use of health products in maintaining its quality, safety and efficacy, as well as the effectiveness of the Field Action, expressed by RDC 23/2012: "(...) Art 2 ° A holder of registration of health product is the holder of the registration / registration of health product with Anvisa. Single paragraph. The registration holder, as well as other agents involved from the production to the use of the product, or discarding it when applicable, are jointly and severally responsible for maintaining the quality, safety and efficacy of the health products to the final consumer. Art. 12 Distributors of health products shall forward to the registration holder, in a timely manner, the distribution map and other information requested for the notification and execution of field actions. (...) "